Not long after political candidates pointed to astronomical drug prices on the debate stage, new analysis showed that the average price of new brand-name drugs skyrocketed in the last decade. Current and future politicians linger in a limbo of promises that can’t be immediately acted on. To date, most governmental drug pricing proposals have been delayed or rescinded by the Trump administration. And pharmaceutical industry regulators, too, have been slow to make much progress on drug prices within a Byzantine mire of authorities.

Meanwhile, pharmacy giants are in a feeding frenzy, with transactions like Amgen’s purchase of Celgene’s psoriasis drug clearing a roadblock for Bristol-Myers Squibb’s acquisition of Celgene.

Drug companies are getting bigger and health care costs keep going up. What can employers do now to fight back in this David versus Goliath setup, as the sides become increasingly uneven?

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2022 ALM Global, LLC. All Rights Reserved.